Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This is a single-site study. One purpose of this trial is to extend the safety and efficacy
evidence basis for Azstarys in adults with ADHD. This open-label, treatment study will
examine the efficacy of Azstarys on ADHD symptoms using the AISRS 18-item total score on the
AISRS-expanded; the Adult ADHD Investigator Symptom Rating Scale. The investigators will also
examine Executive Function later in the day (early evening, about 12 hours after first
morning dosing).